from Breakingviews:

TPG’s $8 bln drug sale far from generic

May 18, 2015

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Danaher breakup eases sting of pricey Pall deal

May 13, 2015

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Pure play gets new spin in filter maker M&A

May 13, 2015

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Pharma Arbageddon fears keep traders on sidelines

April 27, 2015

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Teva’s $40 bln hostile bid puts hope over reality

April 21, 2015

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Valeant’s $11 bln bid may have scored two knockouts

March 16, 2015

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Deal junkie Valeant shoots up on $10 bln fix

February 23, 2015

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Drugmakers unlikely candidates for next big short

February 11, 2015

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Pfizer’s generics injection lifts mood for breakup

February 5, 2015

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Shire gambles AbbVie break fee on risky $5 bln deal

January 12, 2015

By Neil Unmack

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.